Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT07585032
Recruiting Observational

Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma

NCT07585032 · tracked via the Priya Life Science Sweden tracker
Sponsor
Sahlgrenska University Hospital
Phase
Observational
Started
2025-03-31
Last updated
2026-05-13

Condition(s) studied

Insulinoma; Pancreas

Investigational drug(s) / intervention(s)

EUS-RFA

EUS-RFA: Treatment of insulinoma by EUS-RFA

Study summary

Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.

In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.

Eligibility

Sex
ALL
Min age
15 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Insulinoma verified by pathology (often from EUS-FNB-sampling) Exclusion Criteria: * Patients unwilling to participate * Patients unable to understand and obtain written informed conscent * Severe comorbidity

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sahlgrenska Univeristy Hospital Gothenburg Sweden Recruiting

More Sahlgrenska University Hospital trials in Sweden

Placebo Effect In Spinal Cord Electrical Stimulation for Pain Recruiting
Incidence, Treatment and Outcome After Acute Mesenteric Ischemia in the Region of Västra Götaland, 2000-2023. Active, not recruiting
Watch and Wait as Treatment for Patients With Rectal Cancer Recruiting
Predicting Colorectal Cancer - Tissue Samples to Evaluate Tumour Characteristics and Treatment Response Recruiting
Reperfusion Treatment in Acute Pulmonary Embolism Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07585032 on ClinicalTrials.gov ↗ ← All trials in Sweden